Chronic Obstructive Pulmonary Disease (COPD) Market will increase to around USD 22.91 Billion by 2028 according to the publisher. Chronic inflammatory lung disease causes breathing difficulties. It is a group of progressive lung diseases. The most common diseases are emphysema and chronic bronchitis. COPD, if left untreated, can lead to worsening respiratory infection, heart problems, and the progression of various other diseases.Worldwide Chronic Obstructive Pulmonary Disease (COPD) Market was at US$ 16.40 Billion in 2022
COPD is commonly caused due to smoking tobacco-related products. The longer and more tobacco products an individual smokes, the greater risk of having COPD. Cigarette smoking, cigar smoke, pipe smoke, and second-hand smoke can also cause COPD. According to World Health Organization (WHO), COPD is considered the third leading cause of death worldwide, and nearly 90% of Global Chronic Obstructive Pulmonary Disease deaths in those under 70 years of age occur in low and medium income countries (LMIC).
Worldwide Chronic Obstructive Pulmonary Disease Market will grow at a CAGR of 5.73% from 2022 to 2028
The rise in the incidence of COPD is the major contributor to the market's growth. In addition, people's lifestyle change is responsible for increasing habits like smoking and drinking. The other factors that influence the growth of the COPD market are a rise in demand for medications for the treatment of COPD symptoms, an increase in funding for R&D and drug production by government and pharmaceutical companies, growing awareness among people across developing and underdeveloped countries, are boosting the growth of the market companies. Nevertheless, the high cost of COPD treatment and lack of knowledge about COPD is anticipated to hinder the market's growth. Also, factors like patent expiry for medical devices will restrict the development of the market.Chronic Bronchitis will lead in Chronic Obstructive Pulmonary Disease Market
Based on type, the global COPD market is categorized into; chronic bronchitis and emphysema. The chronic bronchitis category dominates the market share of the worldwide COPD market. The reason for its dominance is the growing incidence and prevalence of chronic bronchitis worldwide, due to the rise in the consumption of cigarettes and the increase in industrialization, which results in air pollution and the release of harmful gases into the environment.Drug remain the most important segment in Treatment Type
Based on treatment, the global COPD market is divided into; drugs, oxygen therapy, surgery, and others. The drugs segment has a higher market share in the market, owing to the increasing use of drugs as the first line of treatment for COPD to make breathing easier by widening airways.The oxygen therapy market is also expected to surge at a significant CAGR rate in the forecast period. The growth can be attributed to factors like the rapid growth of the geriatric population, the rising prevalence of tobacco smoking, the development of respiratory disorders, the increase in the usage of home-based oxygen therapy, and technological advancements.
Rise in Number of COPD Therapeutics Dispensed to boost the hospital Segment
The distribution channels can be segmented into; hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment has a high market share. The dominance due to the rising number of patients suffering from chronic respiratory diseases and rising awareness about these diseases. Furthermore, the availability of various diagnostics and treatment facilities and higher purchasing power has contributed to the segment's growth.North American area dominates the COPD Industry
The report divides the region into; North America, Europe, Asia-Pacific, Latin America, and Middle-East & Africa. The North American area dominates the market share. This can be attributed to increased investment in R&D activities to develop innovative drugs for treating diseases. Also, the rise in an older population, rising incidence and prevalence of chronic respiratory diseases, technological advancement, growing healthcare sectors, and massive presence of leading market players are some of the major factors that boost the COPD Market in the region.The Asia-Pacific region is forecasted to have significant growth, owing to increasing focus on the development of healthcare infrastructure, rising prevalence of various chronic respiratory diseases along with lifestyle diseases, rise in industrialization, changes in the lifestyle, and increase in the patient population suffering from COPD in the developing nations such as China, and India. According to our research report, Worldwide Chronic Obstructive Pulmonary Disease (COPD) Market was at US$ 16.40 Billion in 2022.
Key Players in Chronic Obstructive Pulmonary Disease Market
COPD market is consolidated with the presence of a small number of key players. Also, the key players are constantly involved in product innovation and development, technological advancements, agreements, mergers, and acquisitions to procure a higher market share. The key players in the market are; AstraZeneca, Pfizer Inc., GlaxoSmithKline Plc, Novartis AG, Astellas Pharma, Abbott Laboratories, Boehringer Ingelheim International GmbH, and Almirall.For instance, In Nov 2021, AstraZeneca announced that sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company CovisPharma Group for US$ 270 Mn. These products are indicated for treating chronic obstructive pulmonary disease (COPD).
The report titled “Chronic Obstructive Pulmonary Disease Market, Global Forecast by Product Type (Chronic Bronchitis and Emphysema), Treatment (Drugs, Oxygen Therapy, Surgery & Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), Regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Company Analysis (AstraZeneca, Pfizer, Inc, GlaxoSmithKline plc., Novartis AG, AstellasPharmaInc, Abbott Laboratories, BoehringerIngelheim International GmbH&Almirall)” Provides a detailed analysis of Chronic Obstructive Pulmonary Disease Market.
Product Types - Market has been covered from 2 viewpoints
1. Chronic Bronchitis2. Emphysema
Treatment- Market has been covered from 4 viewpoints
1. Drugs2. Oxygen Therapy
3. Surgery
4. Others
Distribution Channels - Market has been covered from 3 viewpoints
1. Hospital Pharmacies2. Retail Pharmacies
3. Online Pharmacies
Distribution Channels - Market has been covered from 5 viewpoints
1. North America2. Europe
3. Asia Pacific
4. Latin America
5. Middle East & Africa
All the companies have been studied from 3 points
- Overview
- Recent Developments
- Sales Analysis
Company Analysis
1. AstraZeneca2. Pfizer, Inc
3. GlaxoSmithKline plc
4. Novartis AG
5. AstellasPharma Inc.
6. Abbott Laboratories
7. BoehringerIngelheim International GmbH
8. Almirall
Table of Contents
1. Introduction2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Chronic Obstructive Pulmonary Disease Copd Market
6. Market Share - Global Acute Respiratory Distress Syndrome
6.1 By Type
6.2 By Treatment
6.3 By Distribution Channels
6.4 By Regions
7. Types - Chronic Obstructive Pulmonary Disease Copd Market
7.1 Chronic Bronchitis
7.2 Emphysema
8. Treatment Types -Chronic Obstructive Pulmonary Disease Copd Market
8.1 Drugs
8.2 Oxygen Therapy
8.3 Surgery
8.4 Others
9. Distribution Channels -Chronic Obstructive Pulmonary Disease Copd Market
9.1 Hospital Phamacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
10. Regions - Chronic Obstructive Pulmonary Disease Copd Market
10.1 North America
10.2 Europe
10.3 Asia - Pacific
10.4 Latin America
10.5 Middle East & Africa
11. Company Analysis
11.1 AstraZeneca
11.1.1 Overview
11.1.2 Recent Developments
11.1.3 Sales Analysis
11.2 Pfizer, Inc.
11.2.1 Overview
11.2.2 Recent Developments
11.2.3 Sales Analysis
11.3 GlaxoSmithKline plc.
11.3.1 Overview
11.3.2 Recent Developments
11.3.3 Sales Analysis
11.4 Novartis AG
11.4.1 Overview
11.4.2 Recent Developments
11.4.3 Sales Analysis
11.5 AstellasPharma Inc.
11.5.1 Overview
11.5.2 Recent Developments
11.5.3 Sales Analysis
11.6 Abbott Laboratories
11.6.1 Overview
11.6.2 Recent Developments
11.6.3 Sales Analysis
11.7 BoehringerIngelheim International GmbH
11.7.1 Overview
11.7.2 Recent Developments
11.7.3 Sales Analysis
11.8 Almirall
11.8.1 Overview
11.8.2 Recent Developments
11.8.3 Sales Analysis
List of Figures:
Figure 01: Global - Chronic Obstructive Pulmonary Disease Market (Billion US$), 2018 - 2022
Figure 02: Global - Forecast for Chronic Obstructive Pulmonary Disease Market (Billion US$), 2023 - 2028
Figure 03: Type - Chronic Bronchitis Market (Million US$), 2018 - 2022
Figure 04: Type - Forecast for Chronic Bronchitis Market (Million US$), 2023 - 2028
Figure 05: Type - Emphysema Market (Million US$), 2018 - 2022
Figure 06: Type - Forecast for Emphysema Market (Million US$), 2023 - 2028
Figure 07: Treatment Type - Drugs Market (Million US$), 2018 - 2022
Figure 08: Treatment Type - Forecast for Drugs Market (Million US$), 2023 - 2028
Figure 09: Treatment Type - Oxygen Therapy Market (Million US$), 2018 - 2022
Figure 10: Treatment Type - Forecast for Oxygen Therapy Market (Million US$), 2023 - 2028
Figure 11: Treatment Type - Surgery Market (Million US$), 2018 - 2022
Figure 12: Treatment Type - Forecast for Surgery Market (Million US$), 2023 - 2028
Figure 13: Treatment Type - Others Market (Million US$), 2018 - 2022
Figure 14: Treatment Type - Forecast for Others Market (Million US$), 2023 - 2028
Figure 15: Distribution Channel - Hospital Phamacies Market (Million US$), 2018 - 2022
Figure 16: Distribution Channel - Forecast for Hospital Phamacies Market (Million US$), 2023 - 2028
Figure 17: Distribution Channel - Retail Pharmacies Market (Million US$), 2018 - 2022
Figure 18: Distribution Channel - Forecast for Retail Pharmacies Market (Million US$), 2023 - 2028
Figure 19: Distribution Channel - Online Pharmacies Market (Million US$), 2018 - 2022
Figure 20: Distribution Channel - Forecast for Online Pharmacies Market (Million US$), 2023 - 2028
Figure 21: North America - Chronic Obstructive Pulmonary Disease Market (Million US$), 2018 - 2022
Figure 22: North America - Forecast for Chronic Obstructive Pulmonary Disease Market (Million US$), 2023 - 2028
Figure 23: Europe - Chronic Obstructive Pulmonary Disease Market (Million US$), 2018 - 2022
Figure 24: Europe - Forecast for Chronic Obstructive Pulmonary Disease Market (Million US$), 2023 - 2028
Figure 25: Asia - Pacific - Chronic Obstructive Pulmonary Disease Market (Million US$), 2018 - 2022
Figure 26: Asia - Pacific - Forecast for Chronic Obstructive Pulmonary Disease Market (Million US$), 2023 - 2028
Figure 27: Latin America - Chronic Obstructive Pulmonary Disease Market (Million US$), 2018 - 2022
Figure 28: Latin America - Forecast for Chronic Obstructive Pulmonary Disease Market (Million US$), 2023 - 2028
Figure 29: Middle East & Africa - Chronic Obstructive Pulmonary Disease Market (Million US$), 2018 - 2022
Figure 30: Middle East & Africa - Forecast for Chronic Obstructive Pulmonary Disease Market (Million US$), 2023 - 2028
Figure 31: AstraZeneca - Global Revenue (Billion US$), 2018 - 2022
Figure 32: AstraZeneca - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 33: Pfizer, Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 34: Pfizer, Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 35: GlaxoSmithKline plc. - Global Revenue (Billion US$), 2018 - 2022
Figure 36: GlaxoSmithKline plc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 37: Novartis AG - Global Revenue (Billion US$), 2018 - 2022
Figure 38: Novartis AG - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 39: AstellasPharma Inc. - Global Revenue (Billion US$), 2018 - 2022
Figure 40: AstellasPharma Inc. - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 41: Abbott Laboratories - Global Revenue (Billion US$), 2018 - 2022
Figure 42: Abbott Laboratories - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 43: BoehringerIngelheim International GmbH - Global Revenue (Billion US$), 2018 - 2022
Figure 44: BoehringerIngelheim International GmbH - Forecast for Global Revenue (Billion US$), 2023 - 2028
Figure 45: Almirall - Global Revenue (Million US$), 2018 - 2022
Figure 46: Almirall - Forecast for Global Revenue (Million US$), 2023 - 2028
List of Tables:
Table 01: Global - Chronic Obstructive Pulmonary Disease Market Share by Type (Percent), 2018 - 2022
Table 02: Global - Forecast for Chronic Obstructive Pulmonary Disease Market Share by Type (Percent), 2023 - 2028
Table 03: Global - Chronic Obstructive Pulmonary Disease Market Share by Treatment Type (Percent), 2018 - 2022
Table 04: Global - Forecast for Chronic Obstructive Pulmonary Disease Market Share by Treatment Type (Percent), 2023 - 2028
Table 05: Global - Chronic Obstructive Pulmonary Disease Market Share by Distribution Channels (Percent), 2018 - 2022
Table 06: Global - Forecast for Chronic Obstructive Pulmonary Disease Market Share by Distribution Channels (Percent), 2023 - 2028
Table 07: Global - Chronic Obstructive Pulmonary Disease Market Share by Region (Percent), 2018 - 2022
Table 08: Global - Forecast for Chronic Obstructive Pulmonary Disease Market Share by Regions(Percent), 2023 - 2028
Companies Mentioned
- AstraZeneca
- Pfizer, Inc
- GlaxoSmithKline plc
- Novartis AG
- AstellasPharma Inc.
- Abbott Laboratories
- BoehringerIngelheim International GmbH
- Almirall
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 125 |
| Published | January 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 16.4 Billion |
| Forecasted Market Value ( USD | $ 22.91 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
